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Abstract
Purpose The goal of chemotherapy for metastatic breast
cancer (MBC) is to prolong survival and maintain health-
related quality of life. This study aimed to evaluate long-
term health status of patients with MBC who participated
in the phase III randomized SELECT BC trial.
Methods In the SELECT BC trial, patients were randomly
allocated to the S-1 or taxane (paclitaxel or docetaxel) arm.
Health status was assessed by EQ-5D at pre-treatment, 3
and 6 months after randomization, and every 6 months
thereafter to the extent possible. Least square mean scores
were assessed to compare EQ-5D index values between
groups. Time to deterioration analysis was also performed
by defining the minimally important difference of EQ-5D
as 0.05 or 0.1.
Results The number of patients for EQ-5D analysis was
175 and 208 in the taxane and S-1 arms, respectively. Least
square mean EQ-5D index values up to 60 months were
0.741 (95 % CI [0.713–0.769]) in the taxane arm and 0.748
[0.722–0.775] in the S-1 arm. The EQ-5D index value
during PFS up to 12 months in the S-1 was superior to the
corresponding index value in the taxane (0.812
[0.789–0.834] vs. 0.772 [0.751–0.792], P = 0.009). Time
to deterioration analysis also revealed that S-1 significantly
delayed the deterioration of EQ-5D index value during the
period before progression (P = 0.002 and 0.003).
Conclusions Our findings suggest that the EQ-5D index
value was higher in patients treated with S-1 during first-
line chemotherapy. Considering non-inferiority of S-1 in
terms of OS, obtained quality-adjusted life years may be
greater in the S-1 arm.
Keywords Breast cancer  EQ-5D  Health-related quality
of life  Randomized controlled trial  S-1  Taxane
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Introduction
Breast cancer has the highest incidence among cancers in
women worldwide, with a global age-standardized rate per
100,000 of 51.7 (75.0 in developed countries), correspond-
ing to an increase of 16.6 % from 1990 [1]. Breast cancer is
also amajor factor that leads to death during the reproductive
years [2]. Although diagnosis and treatment of breast cancer
have advanced substantially in the past decade, breast cancer
is still a common disease that affects the health-related
quality of life (HRQOL) of patients and their families, and
contributes significantly to healthcare costs.
The goal of chemotherapy for metastatic breast cancer
(MBC) is to prolong survival and maintain HRQOL.
Taxane and anthracycline are the first choice of
chemotherapy for MBC, although these agents can reduce
the HRQOL of some patients due to adverse events such as
hair loss, peripheral neuropathy, and edema [3, 4]. Patients
also frequently need to visit the hospital in order to receive
intravenous chemotherapy, which leads to loss of produc-
tivity. S-1 [5] is an oral fluoropyrimidine drug for gastric
and other cancers. While continuous infusions of 5-FU are
known to be more effective than bolus injections for col-
orectal cancer patients [6], S-1 offers an advantageous and
convenient alternative in that the maintenance of thera-
peutic blood levels of fluorouracil can be achieved with
oral tablets alone, without requiring an injection pump.
SELECT BC is a phase III open-label randomized
controlled trial (RCT) that compared S-1 with taxane for
first-line MBC therapy [7]. The trial demonstrated non-
inferiority of S-1 to taxane in overall survival (OS); median
OS was 37.2 months in the taxane arm and 35.0 months in
the S-1 arm (hazard ratio (HR) 1.05, 95 % CI 0.86–1.27,
P = 0.015) at a median follow-up of 34.6 months.
SELECT BC also assessed HRQOL as a secondary end-
point using two instruments: the European Organisation for
Research and Treatment of Cancer Core Quality of Life
Questionnaire C30 (EORTC QLQ-C30) [8] and the three-
level version of the EuroQol five-dimensional questionnaire
(EQ-5D-3L) [9]. In terms of the primary endpoint, neither
treatment is superior to the other; however, our hypothesis
expected HRQOL in the S-1 group to be better than in the
taxane group. This finding highlights the importance of
considering HRQOL in the selection of chemotherapy. In
some randomized phase III trials [10–20], the HRQOL of
MBC patients was reported using the Functional Assessment
of Cancer Therapy (FACT) or EORTC, which are both
standard cancer-specific instruments.
In this paper, we report our findings from the long-term
data on EQ-5D-3L, which is the most commonly used
preference-based measure [21, 22]. EQ-5D-3L index val-
ues can be also used to calculate quality-adjusted life years
(QALYs) for the economic evaluation of healthcare tech-
nologies. As cost-effectiveness is included as a secondary
endpoint of this trial, EQ-5D-3L index values will be also
used for economic evaluation. In the SELECT BC trial,
EQ-5D-3L measurements were continued over a prolonged
period of time because measurements could be continued
even when the disease progressed, whereas EORTC QLQ-
C30 measurements were taken only during the first year. In
many studies, measurements are stopped at the pre-deter-
mined time point or at disease progression. Thus, the long-
term index value is often unknown. Against this backdrop,
we report long-term EQ-5D-3L index values of MBC
patients measured to the extent possible, i.e., until death.
Methods
Study design
In the SELECT BC trial, patients with HER2-negative,
hormone-resistant MBC, who were not previously treated
with chemotherapy after diagnosis, were randomized at a
1:1 ratio and allocated to the taxane (docetaxel 60–75 mg/
m2 q3w, paclitaxel 80–100 mg/m2 q1w, or paclitaxel
175 mg/m2 q3w at the discretion of the treating physician)
or S-1 (40–60 mg twice daily based on the patient’s body
surface area, for 28 days on and 14 days off) arm. Treat-
ment continued until the disease progressed or more than 4
cycles of S-1 or 6 cycles of taxane were administered.
The enrollment period of the SELECT BC trial was from
October 2006 to July 2010, involving 154 institutions. Some
of the randomized patients participated in this HRQOL
survey. Selection of HRQOL respondents was based on the
institution; i.e., some institutions were excluded in advance
due to feasibility issues. As institution was a prognostic
factor for dynamic allocation, patient background factors
were expected to be balanced in both arms.
The study was conducted in accordance with the Ethical
Guidelines for Clinical Research of the Japanese Ministry
of Health, Labour and Welfare and the Declaration of
Helsinki. Written informed consent was obtained from
each participant. Approval for the protocol and for any
modifications was obtained from an independent ethics
committee for each participating site. SELECT BC was
prospectively registered with the University Hospital
Medical Information Network (UMIN) in Japan (protocol
ID C000000416).
EQ-5D assessment
The EQ-5D comprises five items: ‘‘mobility,’’ ‘‘self-care,’’
‘‘usual activities,’’ ‘‘pain/discomfort,’’ and ‘‘anxiety/
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depression,’’ which were assessed at three levels of
description. Responses can be converted to an EQ-5D
index value using a predetermined algorithm based on
societal preferences of the general population.
In the SELECT BC trial, patients were asked to respond
to the Japanese version of EQ-5D at baseline, 3, 6,
12 months, and every 6 months thereafter until death or to
the extent possible. In general, patients responded to the
EQ-5D just before the next cycle of chemotherapy was
administered. In this study, a change of 0.05 or 0.1 was
considered the minimal important difference (MID)
[23–25], which corresponds to the smallest improvement
(or deterioration) considered to be worthwhile by the
patient.
Outcome
The predetermined endpoint for EQ-5D is the comparison
of longitudinal EQ-5D index values between groups. In
addition, explanatory analysis was performed for the fol-
lowing endpoints: time to deterioration by MID during OS
and progression-free survival (PFS) and the longitudinal
index value after progression and index values before
death.
Statistical analysis
The planned sample population for the HRQOL analysis
was approximately 300; this number was not based on a
statistical calculation because HRQOL in the SELECT BC
trial was not the confirmatory endpoint. Collected respon-
ses were converted to EQ-5D index values using the
Japanese scoring algorithm [26].
Linear mixed models for repeated measures (MMRM)
were applied to compare EQ-5D index values between the
two groups. The analysis used all data, including those
after disease progression. EQ-5D index values were
adjusted by baseline index value, time, and treatment-by-
time interaction. Patient was also added to the model as a
random variable. Estimates of the least square means for
EQ-5D index values and 95 % confidence intervals (CIs)
were calculated by each visit and group. An estimated EQ-
5D index value during first-line treatment was also calcu-
lated, and MMRM was used with progression being cen-
sored even if EQ-5D index values were actually measured
afterward.
One of the secondary analyses was time to deterioration,
with the time assessed using survival analysis. The defi-
nition of deterioration was based on the reported MID of
EQ-5D: 0.05 or 0.1 relative to the baseline index value.
Only the first deterioration was defined as an event. In this
analysis, death was also treated as an event because the
EQ-5D index value of deceased patients is normally
considered to be 0. Another related analysis was time to
deterioration during the progression-free period. In this
analysis, progression was treated as a competing risk and
death as an event. Cumulative incidence function (CIF),
Gray’s test [27], and Fine and Gray’s proportional hazard
model [28] were applied to these data with competing risk.
Longitudinal index values after progression and before
death were also estimated by MMRM. With regard to index
values before death, the simple least square mean of index
values could potentially have selection bias if the responses
of patients with lower EQ-5D index values are more likely
to be missing. For example, it may be difficult for end-of-
life patients to complete the EQ-5D instrument. To check
for potential biases, logistic regression was used to confirm
the relationship between ‘‘probability of missing at visit
0–6 months before death’’ and ‘‘EQ-5D index value of last
observation except at 0–6 months before death.’’




Participants were 618 Japanese MBC patients who were
randomly assigned to either the taxane (n = 309) or S-1
(n = 309) arm. In total, 175 and 208 patients in the taxane
and S-1 arms, respectively, were included in the HRQOL
analysis. In the taxane arm, 96 patients received docetaxel,
and 79 received paclitaxel. The CONSORT diagram for
study enrollment is shown in Fig. 1. Baseline characteris-
tics of patients were balanced in the two arms (Table 1).
EQ-5D completion rates
Longitudinal EQ-5D completion rates are shown in
Table 2. Mean duration of the EQ-5D response was
21 months for both groups. Completion rates at 3 months
were 88.3 and 83.6 % in the taxane and S-1 arms,
respectively, and 71.8 and 77.6 %, respectively, at
12 months. Although the percentage gradually declined
with time, more than half of the patients completed the
instrument at 60 months (with the exception of 42 and
48 months in the taxane arm).
Longitudinal analysis of EQ-5D index values
Estimated EQ-5D least square means and 95 % CI are
shown longitudinally in Fig. 2a. Least square means for
index values up to 60 months were 0.741 (95 % CI
[0.713–0.769]) and 0.748 (95 % CI [0.722–0.775]) in the
taxane and S-1 arms, respectively (Table 3). No significant
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differences in index values were observed between the
taxane and S-1 arms up to 60 months (group: P = 0.712,
interaction of group and time: P = 0.691).
Figure 2b shows longitudinal index values and 95 % CI
during PFS. This analysis censored responses after pro-
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Fig. 1 CONSORT diagram
Table 1 Baseline
characteristics
Taxane (N = 175) S-1 (N = 208)
Median age (range) 57.0 (33–75) 59.0 (29–75)
Hormone receptor status
ER positive, PgR positive, or both 127 (72.6) 149 (71.6)
ER negative and PgR negative 45 (25.7) 53 (25.5)
Unknown 3 (1.7) 6 (2.9)
HER2 status
Negative 162 (92.6) 192 (92.3)
Unknown 13 (7.4) 16 (7.7)
Components of (neo)adjuvant treatment
Oral fluoropyrimidine 26 (14.9) 22 (10.6)
Taxane 49 (28.0) 61 (29.3)
Endocrine therapy 100 (57.1) 111 (53.4)
Disease-free interval
B2 years 34 (19.4) 41 (19.7)
2–5 years 52 (29.7) 66 (31.7)
C5 years 58 (33.1) 67 (32.2)
No surgery 31 (17.7) 34 (16.3)
Liver metastasis
Yes 61 (34.9) 78 (37.5)
No 114 (65.1) 130 (62.5)
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significantly differed between the two arms (group:
P = 0.009, interaction of group and time: P = 0.966). The
period of 12 months approximately corresponds to the
duration of chemotherapy, since the median time to treat-
ment failure (TTF) was 8–9 months. Least square means of
index values up to 12 months were 0.772 (95 % CI
[0.751–0.792]) and 0.812 (95 % CI [0.789–0.834]) in the
taxane and S-1 arms, respectively, and index values up to
36 months were 0.781 (95 % CI [0.754–0.809]) and 0.811
(95 % CI [0.781–0.841]), respectively.
Time to deterioration analysis
Figure 3 shows two different time to deterioration anal-
yses, in which 0.05 and 0.1 were used as the MID. First,
Fig. 3a shows the deterioration-free rate for all survival
periods up to 60 months. Deterioration-free rates did not
significantly differ between arms, regardless of the MID.
Median time to deterioration was 12.0 and 15.2 months
in the taxane and S-1 arms, respectively, when 0.05 was
used as the MID. When 0.1 was used as the MID, the
time was extended to 15.2 and 23.6 months in the taxane
and S-1 arms, respectively. Hazard ratios for the S-1 arm
were 0.896 (MID = 0.05, 95 %CI [0.719–1.118],
P = 0.331) and 0.875 (MID = 0.1, 95 %CI
[0.699–1.096], P = 0.244).
Deterioration rates during progression-free survival were
compared by treating progression as a competing risk. Fig-
ure 3b shows CIF of both arms. In this analysis, hazard ratios
for the S-1 arm were significantly lower than 1, i.e., 0.580
(MID = 0.05, 95 %CI [0.410–0.820], P = 0.002) and
0.536 (MID = 0.1, 95 %CI [0.357–0.804], P = 0.003).
Index values after progression/before death
A total of 234 patients (96 in taxane arm and 138 in S-1
arm) had responses after progression. Mean index values
were estimated from pooled data (Fig. 4a) because the
index values did not significantly differ between arms
(group: P = 0.877, interaction of group and time:
P = 0.586). The mean index value after progression was
0.721 (95 %CI [0.698–0744]), which is lower than the
index value during first-line treatment.
Table 2 EQ-5D completion rate
Taxane (N = 175) S-1 (N = 208)
Baseline 175/175 (100) 208/208 (100)
Month 3 151/171 (88.3) 168/201 (83.6)
Month 6 138/168 (82.1) 146/190 (76.8)
Month 12 107/149 (71.8) 132/170 (77.6)
Month 18 75/126 (59.5) 107/158 (67.7)
Month 24 68/117 (58.1) 93/137 (67.9)
Month 30 51/101 (50.5) 68/110 (61.8)
Month 36 45/90 (50.0) 47/84 (56.0)
Month 42 27/61 (44.3) 31/61 (50.8)
Month 48 18/39 (46.2) 21/37 (56.8)
Month 54 15/23 (65.2) 14/19 (73.7)



































































































Fig. 2 Longitudinal mean and 95% confidence interval of EQ-5D
index values. a Scores during overall survival. b Scores before
progression
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With respect to index values before death, 256 deaths
(116 in taxane arm and 140 in S-1 arm) occurred; 156
responses were collected 0–6 months before death. Mean
index values did not significantly differ between arms
(Fig. 4b). These results indicate that mean index values
decreased gradually as death approached. Logistic analysis
revealed that the probability of missing at 0–6 months
before death was not significantly correlated with the index
value at the last observation (P = 0.158). Selection bias in
which patients with lower EQ-5D index values tended to
drop out was not detected.
Discussion
HRQOL is an important outcome for patients with MBC.
Our study surveyed long-term EQ-5D index values in the
phase III randomized SELECT BC trial, which compared
S-1 with taxane as first-line treatments for patients with
MBC. We found that EQ-5D index values of respondents
were higher in the S-1 arm than in the taxane arm, when the
analysis was limited to the first 12 months during PFS.
Grade 3 or higher adverse events (AE) including edema
and sensory neuropathy occurred significantly more fre-
quently in the taxane group, whereas diarrhea, mucositis,
and nausea were more frequent in the S-1 group [7]. Dif-
ferent AE patterns might have influenced EQ-5D index
values. EQ-5D index values did not differ between the two
arms when observations were continued up to 60 months.
These results may be due to crossover to S-1 at the time of
disease progression or the influence of second-line or
subsequent therapy. These results were supported by the
results of the time to deterioration analysis. A previous
SELECT BC trial report [7] showed that EQ-5D index
values were significantly higher in the S-1 arm for
36 months after randomization. In contrast, the present
study reports EQ-5D index values over a longer period
(60 months), based on more detailed analyses.
EQ-5D index values after progression and before death
were also assessed, although these index values did not
significantly differ between groups. The SELECT BC trial
demonstrated non-inferiority of S-1 to taxane in terms of
OS. Considering our EQ-5D estimates, obtained QALYs
may be greater in the S-1 arm if the EQ-5D index value of
the S-1 arm during chemotherapy is higher.
Table 3 Estimated least square mean EQ-5D index values
Taxane S-1
Least square means [95 % CI]
(a) During survival
Up to 60 months 0.741 [0.713–0.769] 0.748 [0.722–0.775]
Up to 36 months 0.750 [0.728–0.772] 0.776 [0.756–0.796]
(b) During progression-free stage
Up to 36 months 0.781 [0.754–0.809] 0.811 [0.781–0.841]
Up to 12 months 0.772 [0.751–0.792] 0.812 [0.789–0.834]
(c) After progression
Up to 36 months 0.721 [0.698–0744]
(d) Before death
0–6 months before 0.621 [0.584–0.657]
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Fig. 3 Time to deterioration analysis. a Deterioration-free rate during
overall survival. b Deterioration rate before progression
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The completion rate of the instrument was about 85 % at
3 months after randomization, which is the first time point
after baseline. The rate at 12 months was about 75 %. The
completion rate in the phase III CLEOPATRA trial [17], in
which first-line MBC patients were randomly allocated to
pertuzumab plus existing treatment (trastuzumab plus
docetaxel) or placebo plus existing treatment, was 83.9 %
in the placebo arm and 79.9 % in the pertuzumab arm at
9 weeks. Rates decreased to 76.5 and 81.1 % at 54 weeks
(approximately 12 months), respectively. In the random-
ized JGOG3016 trial [29] for stage II–IV ovarian cancer
conducted in Japan, completion rates were 74.5 % for
conventional treatment and 73.0 % in the dose-dense
chemotherapy arm at the third cycle (approximately
9 weeks) and 74.2 and 71.6 % at 12 months after ran-
domization. When considering these rates, ours were sim-
ilar to those of other randomized phase III studies.
We used both the MMRM and the time to deterioration
analysis to compare EQ-5D index values between groups.
Many recent studies have begun to use time to deterioration
analysis. While the analysis may be more widely accepted,
the results depend on various settings, such as the size of
MID and the handling of other events. Indeed, as shown in
Fig. 3, the size of MID clearly influenced the results.
Results also differed depending on whether death or pro-
gression was considered an event or was censored, or
neither. While our analysis treated death as an event, if it
was censored in the sensitivity analysis, the Kaplan–Meier
curves and median time to deterioration would likely have
changed. Standardization of time to deterioration analysis
is reportedly needed to improve transparency and compa-
rability [30].
This study has some limitations. First, the SELECT BC
trial was an open-label trial that compared oral and intra-
venous therapies. Thus, patients could readily determine
which arm they were allocated to. Some patients partici-
pated in the trial in order to receive oral chemotherapy; if
they were not allocated to the preferred arm, their disap-
pointment might have led to decreased EQ-5D index val-
ues. Second, our analysis did not include missing index
values at each time point. MMRM can be applied to data
under the assumption of missing at random, which means
that a missing index value can be predicted by the observed
index value. However, if, for example, the missing index
value depended on the value after drop out, the estimated
index value by MMRM may be biased. Finally, in this
study, EQ-5D was measured at intervals of 3–6 months,
which might have been too long to capture a temporal
deterioration of HRQOL (e.g., AE caused by chemother-
apy), given that EQ-5D asks respondents about their
momentary health state.
In conclusion, our study supports that the EQ-5D index
value for the S-1 arm is higher during first-line
chemotherapy. We also demonstrated that EQ-5D index
values are similar between patients treated with S-1 and
those treated with taxane over a prolonged period of time.
In addition, we reported on EQ-5D index values after
progression and before death. These data can contribute not
only to economic evaluations, but also to the selection of
treatment for first-line MBC patients based on individual
preferences.
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Fig. 4 Longitudinal mean EQ-5D index values after progression and
before death. a Scores after progression. b Scores before death
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